KOD · Kodiak Sciences Inc · Stock research

SYRE

Spyre Therapeutics, Inc.

Two of three lead binaries (SPY001, SPY002 anti-TL1A) printed potential best-in-class; the stock absorbed a ~$399.7M director-fund block sale and sits back near its ~$102 ATH (~$95). Next legs SPY003 IL-23 Part A (guided mid-2026, overdue) and SPY072 RA topline (accelerated to Q3) are the near-term binaries. Platform de-risked, but distribution flags plus ~1:1 R/R to $100–135 targets argue probe-only into an all-time high.

CMPS

COMPASS Pathways Plc

COMP006 Phase 3 in TRD read out positive on 2026-07-07 (26-week durability, 2027 launch reiterated), completing the pivotal package alongside COMP005 and triggering a same-week analyst upgrade cluster; the psychedelic-mental-health narrative is re-accelerating off dead tape on a hard de-risking event with options-flow confirmation.

LQDA

Liquidia Corporation

YUTREPIA ramp plus legal de-risking plus S&P SmallCap 600 inclusion (eff 2026-06-22) drove a +26% run to new highs; the 2026-06-23 '327 trial date passed with no injunction and BTIG doubled its target to $109. Narrative is accelerating, but a fresh buy at $78 chases a stretched 52-wk high already above the ~$72 consensus into a pending bench ruling and visible insider selling.

MIRM

Mirum Pharmaceuticals, Inc.

Rare-disease platform re-rating on stacked de-risking: zilurgisertib FOP PDUFA set for 2026-09-26 after a 99.9% HO-lesion reduction, brelovitug HDV Phase 3 topline due 2H26, and Q1 sales +43% YoY with 2026 guide lifted to $660–680M. Six analyst PT raises ($145–185) into an all-time-high tape.